| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,151 | 0,199 | 15:14 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:52 | XFRA 4A1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCERENO SCIENTIFIC... ► Artikel lesen | |
| Mo | Cereno Scientific AB: Cereno Scientific Sees Strong Investigator Engagement as EPIMODE Phase IIb Trial Advances | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 08.10. | Cereno Scientific AB: Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides an update... ► Artikel lesen | |
| 25.09. | Cereno Scientific AB: Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive... ► Artikel lesen | |
| 26.08. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2026 | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen |
